476 related articles for article (PubMed ID: 27889292)
1. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.
Strober B; Leonardi C; Papp KA; Mrowietz U; Ohtsuki M; Bissonnette R; Ferris LK; Paul C; Lebwohl M; Braun DK; Mallbris L; Wilhelm S; Xu W; Ljungberg A; Acharya N; Reich K
J Am Acad Dermatol; 2017 Mar; 76(3):432-440.e17. PubMed ID: 27889292
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.
Reich K; Leonardi C; Langley RG; Warren RB; Bachelez H; Romiti R; Ohtsuki M; Xu W; Acharya N; Solotkin K; Colombel JF; Hardin DS
J Am Acad Dermatol; 2017 Mar; 76(3):441-448.e2. PubMed ID: 28027825
[TBL] [Abstract][Full Text] [Related]
3. Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis.
Papp KA; Bachelez H; Blauvelt A; Winthrop KL; Romiti R; Ohtsuki M; Acharya N; Braun DK; Mallbris L; Zhao F; Xu W; Walls CD; Strober B
Br J Dermatol; 2017 Dec; 177(6):1537-1551. PubMed ID: 28600810
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials.
Langley RG; Kimball AB; Nak H; Xu W; Pangallo B; Osuntokun OO; Agada N; Reich K
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):333-339. PubMed ID: 30198588
[TBL] [Abstract][Full Text] [Related]
5. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
Genovese MC; Mysler E; Tomita T; Papp KA; Salvarani C; Schwartzman S; Gallo G; Patel H; Lisse JR; Kronbergs A; Leage SL; Adams DH; Xu W; Marzo-Ortega H; Lebwohl MG
Rheumatology (Oxford); 2020 Dec; 59(12):3834-3844. PubMed ID: 32449924
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
Gottlieb AB; Lacour JP; Korman N; Wilhelm S; Dutronc Y; Schacht A; Erickson J; Zhang L; Mallbris L; Gerdes S
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):679-685. PubMed ID: 27696577
[TBL] [Abstract][Full Text] [Related]
7. Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials.
Mease P; Roussou E; Burmester GR; Goupille P; Gottlieb A; Moriarty SR; Benichou O; Adams DH; Xu W; Nash P
Arthritis Care Res (Hoboken); 2019 Mar; 71(3):367-378. PubMed ID: 30156760
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study.
Valenzuela F; de la Cruz Fernandez C; Galimberti RL; Gürbüz S; McKean-Matthews M; Goncalves L; Romiti R
Actas Dermosifiliogr; 2017; 108(6):550-563. PubMed ID: 28342534
[TBL] [Abstract][Full Text] [Related]
9. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
[TBL] [Abstract][Full Text] [Related]
10. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
Reich K; Puig L; Mallbris L; Zhang L; Osuntokun O; Leonardi C
J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1196-1207. PubMed ID: 28370467
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).
Blauvelt A; Gooderham M; Iversen L; Ball S; Zhang L; Agada NO; Reich K
J Am Acad Dermatol; 2017 Nov; 77(5):855-862. PubMed ID: 28917383
[TBL] [Abstract][Full Text] [Related]
12. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Gordon KB; Blauvelt A; Papp KA; Langley RG; Luger T; Ohtsuki M; Reich K; Amato D; Ball SG; Braun DK; Cameron GS; Erickson J; Konrad RJ; Muram TM; Nickoloff BJ; Osuntokun OO; Secrest RJ; Zhao F; Mallbris L; Leonardi CL; ; ;
N Engl J Med; 2016 Jul; 375(4):345-56. PubMed ID: 27299809
[TBL] [Abstract][Full Text] [Related]
13. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
van de Kerkhof PC; Griffiths CE; Reich K; Leonardi CL; Blauvelt A; Tsai TF; Gong Y; Huang J; Papavassilis C; Fox T
J Am Acad Dermatol; 2016 Jul; 75(1):83-98.e4. PubMed ID: 27180926
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
Blauvelt A; Papp KA; Griffiths CEM; Puig L; Weisman J; Dutronc Y; Kerr LF; Ilo D; Mallbris L; Augustin M
Am J Clin Dermatol; 2017 Apr; 18(2):273-280. PubMed ID: 28074446
[TBL] [Abstract][Full Text] [Related]
15. Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension.
Kimball AB; Luger T; Gottlieb A; Puig L; Kaufmann R; Burge R; Lin CY; Yosipovitch G
Acta Derm Venereol; 2018 Jan; 98(1):98-102. PubMed ID: 28929168
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
[TBL] [Abstract][Full Text] [Related]
17. Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure.
Armstrong A; Paul C; Puig L; Boehncke WH; Freeman M; Torii H; Papp K; Griffiths CEM; Blauvelt A; Reich K; Gooderham M; Terui T; Renda L; Agada N; Xu W; Gallo G; Lebwohl MG
Dermatol Ther (Heidelb); 2020 Feb; 10(1):133-150. PubMed ID: 31749092
[TBL] [Abstract][Full Text] [Related]
18. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.
Armstrong AW; Lynde CW; McBride SR; Ståhle M; Edson-Heredia E; Zhu B; Amato D; Nikaï E; Yang FE; Gordon KB
JAMA Dermatol; 2016 Jun; 152(6):661-9. PubMed ID: 26953848
[TBL] [Abstract][Full Text] [Related]
19. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).
Reich K; Leonardi C; Lebwohl M; Kerdel F; Okubo Y; Romiti R; Goldblum O; Dennehy EB; Kerr L; Sofen H
J Dermatolog Treat; 2017 Jun; 28(4):282-287. PubMed ID: 27759463
[TBL] [Abstract][Full Text] [Related]
20. Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis.
Feldman SR; Foster SA; Zhu B; Burge R; Al Sawah S; Goldblum OM
J Drugs Dermatol; 2017 Dec; 16(12):1246-1252. PubMed ID: 29240860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
